Solesence, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLSN research report →
Price Chart
About the company
Solesence, Inc. , formerly known as Nanophase Technologies Corporation, specializes in the development and production of clean-label, inclusive, and mineral-based skincare and cosmetic products. The company collaborates with a diverse range of partners, from major global corporations to independent brands, employing its unique Active Stress Defense™ technology suite.
- CEO
- Kevin Cureton
- IPO
- 1997
- Employees
- 115
- HQ
- Romeoville, IL, US
Get TickerSpark's AI analysis on SLSN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $99.61M
- P/E
- 35.15
- PEG
- -0.05
- P/S
- 1.72
- P/B
- 6.24
- EV/EBITDA
- 22.01
- Div Yield
- 0.00%
- Gross Margin
- 31.88%
- Op Margin
- 6.30%
- Net Margin
- 4.77%
- ROE
- 18.04%
- ROIC
- 11.85%
Latest fiscal year · YoY change
- Revenue
- $62.06M+18.6%
- Gross Profit
- $16.03M-1.0%
- Op Income
- $1.57M
- Net Income
- $1.79M-57.7%
- EPS
- $0.03-57.1%
- OCF Growth
- -534.7%
- FCF Growth
- -314.0%
- 52W High
- $2.30
- 52W Low
- $0.61
- 50D MA
- $0.93
- 200D MA
- $1.05
- Beta
- 1.37
- RSI (14)
- 70
- Avg Volume
- 390.40K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Solésence reported record Q3 2026 revenue and profitability, with margins improving sharply as operational changes took hold, while full-year EBITDA margin guidance was trimmed below double digits.· November 12, 2026
- Q3 revenue hit a record $20.2 million, up 38% year over year from $14.6 million.
- Gross margin expanded to 39.3% from 23.8%, a 1,550 bps increase, helped by better OEE and mix.
- Net income reached a record $3.7 million versus a $1 million net loss last year.
- Management said full-year 2026 should still be a third straight year of record revenue and profit, but EBITDA margins are now expected to be slightly below the prior double-digit target.
- The company expects at least $65 million in shipped and on-hand orders by year-end and sees further margin improvement into 2027.
Third-quarter 2026 revenue was $20.2 million, up 38% from $14.6 million in Q3 2025. Gross margin was 39.3%, up 1,550 basis points from 23.8% a year ago, driven largely by improved OEE, which rose from 40% to 55%. Net income was a record $3.7 million versus a $1 million net loss in the prior-year quarter. Management said 2026 should still be a third consecutive year of record revenue and profit growth, expects at least $65 million in shipped and on-hand orders by year-end, and now sees full-year EBITDA margins slightly below the previously communicated double-digit target, though still improving in Q4 versus the first half.
Kevin Cureton framed the quarter as evidence that Solésence has “turned a meaningful corner” in its Transform and Transcend strategy. He emphasized that lean management changes, expanded manufacturing capacity, and stronger commercial execution should reduce costs as a percentage of revenue over time. He was also upbeat on industry trends, saying the blurring of beauty and wellness and the FDA approval of BEMT create a meaningful long-term opportunity for the company’s SPF and skin-health technologies.
Laura Riffner focused on the operating leverage now showing up in the P&L. She cited record revenue of $20.2 million, gross margin of 39.3%, record net income of $3.7 million, and OEE improvement from 40% to 55%, while noting year-to-date direct labor costs were down by over $2 million and indirect labor costs down by over $400,000. She also said the company still expects a 30% gross profit floor for 2026, but full-year EBITDA margins will be slightly below the prior double-digit target because first-half performance was softer; she added that restatements have been completed and internal-control testing is underway.
Investors pressed on why guidance was not raised after a very strong quarter. Management said it is being deliberately conservative and does not want to guide quarter-by-quarter because reorders and new launches are shifting around more than in the past; Laura reiterated the 30% gross profit floor but said EBITDA would be a little below double digits. Analysts also asked whether the margin step-up was a one-time event; Laura said it was not a fluke and should be buildable, while Kevin added that greater growth may come more in 2028 than 2027 as commercial changes work through the cycle. On customer concentration and seasonality, Kevin said larger customers are still growing but the company wants to diversify with more brand partners, and that the business is generally non-seasonal aside from a late Q1/early Q2 launch window for SPF-infused products.
The quarter showed sharp operating leverage, with revenue, gross margin, and net income all setting records. Management believes the lean-management rollout, improving labor efficiency, and stronger product mix can keep margins moving higher, while BEMT and the beauty-wellness trend may open additional product and market opportunities. They also sounded confident that 2026 will finish as another record year and that momentum should carry into 2027.
Management trimmed full-year EBITDA margin expectations below double digits, citing softer first-half performance. They also signaled that the next leg of growth may take time, with Kevin suggesting 2028 could be stronger than 2027 as commercial changes cycle through. Customer concentration remains a topic, and the company still needs to diversify beyond its larger brand partners even as those relationships continue to grow.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 25.9%
- Shares Outstanding
- 70.65M
- Float Shares
- 18.33M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 21 ETFs
Biggest fund positions in SLSN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 24, 25 | WHITMORE R JANET | buy | 1,000 |
| Dec 24, 25 | WHITMORE R JANET | buy | 1,500 |
| Nov 19, 25 | WHITMORE R JANET | buy | 5,000 |
| Nov 19, 25 | WHITMORE R JANET | buy | 5,000 |
| Nov 18, 25 | WHITMORE R JANET | buy | 267 |
| Nov 17, 25 | WHITMORE R JANET | buy | 5,000 |
| Nov 14, 25 | WHITMORE R JANET | buy | 19,789 |
| Sep 3, 26 | Riffner Laura C | other | 0 |
| May 29, 25 | WHITMORE BRADFORD T | buy | 4,189,000 |
| May 29, 25 | WHITMORE BRADFORD T | buy | 2,500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SLSN coverage
Recent articles, reports, and earnings notes.
No research on SLSN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SLSN report →SLSN Soars 86% as It Posts Q3 Earnings on Manufacturing Efficiency
zacks.com · Nov 18
Solesence, Inc. (SLSN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
Solésence Reports Record Third Quarter 2026 Financial Results
globenewswire.com · Nov 12
Solesence (NASDAQ:SLSN) versus BioHarvest Sciences (NASDAQ:BHST) Financial Review
defenseworld.net · Nov 6
Head-To-Head Review: Edgewell Personal Care (NYSE:EPC) and Solesence (NASDAQ:SLSN)
defenseworld.net · Sep 30
Analyzing FitLife Brands (NASDAQ:FTLF) and Solesence (NASDAQ:SLSN)
defenseworld.net · Sep 27
SLSN's Earnings Break-Even in Q2, High Operating Costs Hurt
zacks.com · Aug 25
Solesence, Inc. (SLSN) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.